TGF-beta 3 Antibody

Name: TGF-beta 3 Antibody
Brand: R&D Systems
SKU: AB-244-NA
Price: 529 USD
Availability: InStock

R&D Systems | Catalog # AB-244-NA

Submit a review

Citations (10)

Product Documents

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Validated:

Multi-Species

Cited:

Human, Mouse

Applications

Validated:

Neutralization

Cited:

Western Blot, Neutralization

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

View all TGF-beta 3 Primary Antibodies »

Product Specifications

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant chicken TGF‑ beta 3 and recombinant human TGF‑ beta 3
Ala301-Ser412 (Tyr340Phe)
Accession # P10600

Specificity

Detects TGF‑ beta 3 in direct ELISAs. In direct ELISAs, less than 10% cross-reactivity with recombinant amphibian TGF-beta 5 is observed and less than 5% cross-reactivity with recombinant human (rh) TGF-beta 1, rhTGF-beta 2 and rhLAP (TGF-beta 1) is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for TGF-beta 3 Antibody

TGF‑ beta 3 Inhibition of IL‑4-dependent Cell Proliferation and Neutralization by TGF‑ beta 3 Antibody.

Recombinant Human TGF-beta 3 (Catalog # 243-B3) inhibits Recombinant Mouse IL-4 (Catalog # 404-ML) induced proliferation in the HT-2 mouse T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse IL-4 (7.5 ng/mL) activity elicited by Recombinant Human TGF-beta 3 (0.1 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-TGF-beta 3 Polyclonal Antibody (Catalog # AB-244-NA). The ND₅₀ is typically 1-3 µg/mL.

Applications for TGF-beta 3 Antibody

Application

Recommended Usage

Neutralization

Measured by its ability to neutralize TGF‑ beta 3 inhibition of IL‑4-dependent proliferation in the HT‑2 mouse T cell line. Tsang, M. et al. (1995) Cytokine 7:389. The Neutralization Dose (ND₅₀) is typically 1-3 µg/mL in the presence of 0.1 ng/mL Recombinant Human TGF‑ beta 3 and 7.5 ng/mL Recombinant Mouse IL‑4.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Reconstitution

Reconstitute at 1 mg/mL in sterile PBS.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: TGF-beta 3

TGF-beta 3 (transforming growth factor beta 3) is one of three closely related mammalian members of the large TGF-beta superfamily that share a characteristic cystine knot structure (1‑7). TGF-beta 1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1‑4). Each TGF-beta isoform has some non-redundant functions; for TGF-beta 3, mice with targeted deletion show defects palatogenesis and pulmonary development (2). Human TGF-beta 3 cDNA encodes a 412 amino acid (aa) precursor that contains a 20 aa signal peptide and a 392 aa proprotein (8). A furin-like convertase processes the proprotein to generate an N-terminal 220 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF-beta 3 (8, 9). Disulfide-linked homodimers of LAP and TGF-beta 3 remain non-covalently associated after secretion, forming the small latent TGF-beta 3 complex (8‑10). Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (9, 10). TGF-beta is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins (10). Mature human TGF-beta 3 shows 100%, 99% and 98% aa identity with mouse/dog/horse, rat and pig TGF-beta 3, respectively. It demonstrates cross-species activity (1). TGF-beta 3 signaling begins with high-affinity binding to a type II ser/thr kinase receptor termed TGF-beta RII. This receptor then phosphorylates and activates a second ser/thr kinase receptor, TGF-beta RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK-1.This complex phosphorylates and activates Smad proteins that regulate transcription (3, 11, 12). Contributions of the accessory receptors betaglycan (also known as TGF-beta RIII) and endoglin, or use of Smad-independent signaling pathways, allow for disparate actions observed in response to TGF-beta in different contexts (11).